Profile data is unavailable for this security.
About the company
Citius Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of first-in-class critical care products, with a pipeline of anti-infectives in oncology, adjunct cancer care, stem cell therapy and prescription products. The Company's FDA approved LYMPHIR candidate is a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Its late-stage pipeline also includes Mino-Lok, and CITI-002 (Halo-Lido). Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections (CRBSIs) and central line associated bloodstream infections (CLABSIs). Halo-Lido is a topical formulation of halobetasol propionate, a corticosteroid, and lidocaine that is intended for the treatment of hemorrhoids. The Company is also seeking to develop and commercialize the NoveCite mesenchymal stem cells (NC-iMSCs) to treat acute respiratory conditions with a near term focus on ARDS.
- Revenue in USD (TTM)0.00
- Net income in USD-37.43m
- Incorporated2010
- Employees23.00
- LocationCitius Pharmaceuticals Inc11 Commerce Dr Fl 1CRANFORD 07016-3501United StatesUSA
- Phone+1 (908) 967-6677
- Websitehttps://www.citiuspharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Traws Pharma Inc | 2.85m | 93.35m | 15.34m | 7.00 | 0.068 | 3.01 | -- | 5.39 | 28.24 | 28.24 | 0.4566 | 0.6373 | 0.2662 | -- | 1.38 | 406,571.40 | -124.51 | -151.85 | -517.46 | -207.35 | -- | -- | -467.64 | -21,652.42 | -- | -- | 0.00 | -- | 0.00 | -36.47 | -188.55 | -- | -- | -- |
| P3 Health Partners Inc | 1.44bn | -131.05m | 15.42m | 360.00 | -- | -- | -- | 0.0107 | -40.18 | -40.18 | 442.85 | -5.72 | 1.91 | -- | 14.07 | 4,013,756.00 | -37.78 | -49.89 | -113.11 | -253.77 | -4.05 | -1.15 | -19.83 | -46.73 | -- | -5.36 | 0.9304 | -- | 18.48 | 59.38 | -135.14 | -- | -- | -- |
| Apimeds Pharmaceuticals US Inc | 0.00 | -5.16m | 15.47m | 2.00 | -- | 1.90 | -- | -- | -0.4762 | -0.4762 | 0.00 | 0.6489 | 0.00 | -- | -- | 0.00 | -111.07 | -- | -138.71 | -- | -- | -- | -- | -- | -- | -162.30 | 0.0577 | -- | -- | -- | -78.73 | -- | -- | -- |
| Intensity Therapeutics Inc | 0.00 | -11.74m | 15.85m | 5.00 | -- | 1.70 | -- | -- | -0.638 | -0.638 | 0.00 | 0.1472 | 0.00 | -- | -- | 0.00 | -158.62 | -117.05 | -230.00 | -201.39 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -37.14 | -- | -- | -- |
| Klotho Neurosciences Inc | 0.00 | -11.29m | 16.24m | 3.00 | -- | 1.57 | -- | -- | -0.3264 | -0.3264 | 0.00 | 0.1411 | 0.00 | -- | -- | 0.00 | -180.10 | -- | -197.00 | -- | -- | -- | -- | -- | -- | -1.90 | 0.00 | -- | -- | -- | -556.89 | -- | -- | -- |
| Pasithea Therapeutics Corp | 0.00 | -13.49m | 16.40m | 4.00 | -- | 0.433 | -- | -- | -5.21 | -5.21 | 0.00 | 1.64 | 0.00 | -- | -- | 0.00 | -83.64 | -- | -89.28 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 10.34 | -- | -- | -- |
| Fibrobiologics Inc | 0.00 | -18.50m | 16.70m | 13.00 | -- | 96.91 | -- | -- | -0.4809 | -0.4809 | 0.00 | 0.0026 | 0.00 | -- | -- | 0.00 | -192.59 | -- | -636.43 | -- | -- | -- | -- | -- | -- | -27.09 | 0.9734 | -- | -- | -- | 41.44 | -- | -- | -- |
| LeonaBio Inc | 0.00 | -37.72m | 17.12m | 26.00 | -- | 0.639 | -- | -- | -9.68 | -9.68 | 0.00 | 6.79 | 0.00 | -- | -- | 0.00 | -64.88 | -36.31 | -87.99 | -38.92 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 17.62 | -- | -- | -- |
| Citius Pharmaceuticals Inc | 0.00 | -37.43m | 17.12m | 23.00 | -- | 0.2047 | -- | -- | -3.84 | -3.84 | 0.00 | 3.74 | 0.00 | -- | -- | 0.00 | -32.10 | -29.86 | -52.00 | -35.19 | -- | -- | -- | -- | 0.1257 | -244.30 | 0.0127 | -- | -- | -- | 6.85 | -- | 400.55 | -- |
| Linike Medical Group Ltd | 0.00 | -306.90k | 17.16m | -- | -- | -- | -- | -- | -0.1102 | -0.1102 | 0.00 | -0.153 | 0.00 | -- | -- | -- | -278.62 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -651.26 | -- | -- | -- |
| Lunai Bioworks Inc | 0.00 | -130.98m | 17.21m | 29.00 | -- | -- | -- | -- | -7.51 | -7.51 | 0.00 | -0.5626 | 0.00 | -- | -- | 0.00 | -203.39 | -75.79 | -304.47 | -85.18 | -- | -- | -- | -- | -- | -28.85 | -- | -- | -- | -- | -101.31 | -- | -- | -- |
| IN8bio Inc | 0.00 | -20.66m | 17.38m | 18.00 | -- | 0.6194 | -- | -- | -6.48 | -6.48 | 0.00 | 2.87 | 0.00 | -- | -- | 0.00 | -126.22 | -79.60 | -150.81 | -91.19 | -- | -- | -- | -- | -- | -- | 0.0299 | -- | -- | -- | -1.43 | -- | -10.74 | -- |
| Lixte Biotechnology Holdings Inc | 0.00 | -4.13m | 17.40m | 2.00 | -- | 7.38 | -- | -- | -1.18 | -1.18 | 0.00 | 0.8612 | 0.00 | -- | -- | 0.00 | -114.55 | -113.03 | -130.06 | -121.30 | -- | -- | -- | -- | -- | -1,017.39 | 0.00 | -- | -- | -- | 29.51 | -- | -- | -- |
| Phio Pharmaceuticals Corp | 0.00 | -7.95m | 17.76m | 5.00 | -- | 0.9701 | -- | -- | -2.73 | -2.73 | 0.00 | 1.70 | 0.00 | -- | -- | 0.00 | -91.57 | -73.65 | -107.58 | -86.34 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 33.96 | -- | -57.49 | -- |
| Vyne Therapeutics Inc | 524.00k | -33.79m | 18.97m | 13.00 | -- | 0.5644 | -- | 36.21 | -0.7917 | -0.7888 | 0.0123 | 1.01 | 0.0093 | -- | -- | 40,307.69 | -60.16 | -107.54 | -70.67 | -136.47 | -- | -- | -6,448.47 | -1,720.83 | -- | -- | 0.00 | -- | 18.16 | -- | -42.82 | -- | 60.46 | -- |
Data as of Feb 13 2026. Currency figures normalised to Citius Pharmaceuticals Inc's reporting currency: US Dollar USD
10.03%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Heights Capital Management, Inc.as of 20 Oct 2025 | 1.46m | 7.03% |
| Geode Capital Management LLCas of 31 Dec 2025 | 127.53k | 0.61% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 119.72k | 0.58% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 77.76k | 0.37% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 69.85k | 0.34% |
| UBS Securities LLCas of 31 Dec 2025 | 68.17k | 0.33% |
| Asset Advisory Group, Inc.as of 31 Dec 2025 | 59.01k | 0.28% |
| Susquehanna Financial Group LLLPas of 30 Sep 2025 | 48.19k | 0.23% |
| Northern Trust Investments, Inc.(Investment Management)as of 30 Sep 2025 | 27.03k | 0.13% |
| NewEdge Advisors LLCas of 30 Sep 2025 | 25.40k | 0.12% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
